- Home
- CKPT vs PKBK Comparison
CKPT vs PKBK Comparison
Compare CKPT & PKBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- PKBK
- Stock Information
- Founded
- CKPT 2014
- PKBK 1999
- Country
- CKPT United States
- PKBK United States
- Employees
- CKPT N/A
- PKBK N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- PKBK Major Banks
- Sector
- CKPT Health Care
- PKBK Finance
- Exchange
- CKPT Nasdaq
- PKBK Nasdaq
- Market Cap
- CKPT 214.4M
- PKBK 249.7M
- IPO Year
- CKPT 2017
- PKBK N/A
- Fundamental
- Price
- CKPT $3.61
- PKBK $20.91
- Analyst Decision
- CKPT Strong Buy
- PKBK
- Analyst Count
- CKPT 3
- PKBK 0
- Target Price
- CKPT $10.33
- PKBK N/A
- AVG Volume (30 Days)
- CKPT 2.4M
- PKBK 33.5K
- Earning Date
- CKPT 11-12-2024
- PKBK 01-22-2025
- Dividend Yield
- CKPT N/A
- PKBK 3.40%
- EPS Growth
- CKPT N/A
- PKBK N/A
- EPS
- CKPT N/A
- PKBK 2.33
- Revenue
- CKPT $47,000.00
- PKBK $63,152,000.00
- Revenue This Year
- CKPT N/A
- PKBK N/A
- Revenue Next Year
- CKPT $151,162.55
- PKBK N/A
- P/E Ratio
- CKPT N/A
- PKBK $9.09
- Revenue Growth
- CKPT N/A
- PKBK N/A
- 52 Week Low
- CKPT $1.38
- PKBK $15.24
- 52 Week High
- CKPT $4.50
- PKBK $24.29
- Technical
- Relative Strength Index (RSI)
- CKPT 41.64
- PKBK 28.63
- Support Level
- CKPT $2.98
- PKBK $21.90
- Resistance Level
- CKPT $4.44
- PKBK $22.75
- Average True Range (ATR)
- CKPT 0.42
- PKBK 0.52
- MACD
- CKPT -0.10
- PKBK -0.29
- Stochastic Oscillator
- CKPT 25.66
- PKBK 13.12
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.